drug

Passage of the Amendment to the Advanced Regenerative Biotech Act a Positive Catalyst for Korean and Japanese Cell Therapy Companies

Source Node:
Time Stamp: February 7, 2024 10:49 AM - Modified On: February 7, 2024 - Published By:
Source Cluster:
Republished By Plato

Legislation Puts Renewed Focus on Next-Generation NK Cell Therapies New York, Feb 7, 2024 - (Plato Data) - On Thursday February 2, 2024, the bio industry welcomed the parliament’s passage of a bill that adds regenerative medicine organizations to the list of those considered for human cell management business licenses. The National Assembly passed the “Amendment to the Act on Safety and Support for Advanced Regenerative Medicine and Advanced Biopharmaceuticals” in a plenary session paving the way for certain next generation NK Cell Therapy companies to recognized as a licensed

Lindsay Rosenwald’s Fortress Bio (NASDAQ: FBIO) Spotlight on 2024 Milestones from Subsidiaries

Source Node:
Time Stamp: February 2, 2024 2:30 PM - Modified On: February 2, 2024 - Published By:
Source Cluster:
Republished By Plato

  New York, Feb 2, 2024 - (Plato Data)- Fortress Biotech (Fortress Bio), a unique biotech company led by industry veteran Dr. Lindsay Rosenwald, focused on identifying, in-licensing and developing high-potential marketed drugs and development-stage drug candidates in-house and through its subsidiary partner companies, has announced multiple new milestones to start 2024 with a bang. Avenue Therapeutics Finalizes Phase 3 Study for IV Tramadol with FDA Avenue Therapeutics, a subsidiary of Fortress Bio, has reached a significant milestone in its quest to introduce new therapies for neurologic diseases. The company

Investors Take Note as Corbus Pharma Releases Data for ADC Tumor Candidate

Source Node:
Time Stamp: January 29, 2024 6:55 AM - Modified On: January 29, 2024 - Published By:
Source Cluster:
Republished By Plato

New York, Jan. 29, 2024 - (Plato Data) - Corbus Pharmaceuticals (NASDAQ:CRBP) jumped on Friday after announcing positive data from a small group of cancer patients who received its antibody-drug conjugate (ADC) CRB-701 in a Phase 1 trial. Citing a December data cut in patients with cancers expressing a tumor-associated antigen called nectin-4, Corbus (CRBP) said that CRB-701 led to an objective response rate (ORR) of 43%, including three partial responses. The data from the first eighteen participants who received the first six dose levels represented the readout, which was

NKGEN Biotech Received FDA Approval for Clinical Trials of SKN01 NK Cell Therapy in Alzheimer’s Disease Treatment.

Source Node:
Time Stamp: October 24, 2023 11:54 AM - Modified On: October 24, 2023 - Published By:
Source Cluster:
Republished By Plato

Summary: Progress in Neurodegenerative Research:  NKGen’s Phase 1/2a Clinical Trial for SNK01 on Track for End-of-Year Initiation SANTA ANA, Calif., Oct. 24, 2023 (Plato / Amplifi) -- Today, NKGen Biotech Inc. (Nasdaq: NKGN), a trailblazer in the field of autologous, allogeneic, and CAR-NK natural killer cell therapeutics, proudly announced the progression of its SNK01 program targeting Alzheimer’s Disease (AD), backed by the green light from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application. NKGen is gearing up to initiate its Phase 1/2a clinical trial

Cardiol Therapeutics (NASDAQ: CRDL) Advancements in Therapies for Inflammatory Heart Diseases

Source Node:
Time Stamp: October 13, 2023 5:16 AM - Modified On: October 13, 2023 - Published By:
Source Cluster:
Republished By Plato

In the United States, heart disease accounts for a significant number of deaths every year, with cardiovascular disease being the primary concern. Factors like lifestyle choices and unforeseen circumstances contribute to its prevalence. Myocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the heart's lining) are two inflammatory heart conditions primarily linked to immunological reactions from viral infections and mRNA vaccines. Though considered rare, awareness of these conditions is growing, especially among younger populations. Recent research in Science Immunology highlighted an increase in cytokine production leading to myocarditis in

Revolutionizing Clinical Trials: The Digital Watermarking and AI Duo

Source Node:
Time Stamp: October 5, 2023 11:22 AM - Modified On: October 5, 2023 - Published By:
Source Cluster:
Republished By Plato

Revolutionizing Clinical Trials: The Digital Watermarking and AI Duo Clinical trials, the linchpin of medical research, have long been riddled with inefficiencies, from patient recruitment bottlenecks to data management hurdles. As a technology and banking analyst, I've seen how digital solutions can overhaul entire sectors, offering improved productivity and streamlined processes. It's high time that clinical trials get a dose of such digital innovation, and there's a potent combination on the horizon: digital watermarking coupled with Artificial Intelligence (AI). At first glance, one might wonder: how can a technique often

The Convergence of MedTech and Blockchain: Transforming Healthcare

Source Node:
Time Stamp: September 14, 2023 4:39 PM - Modified On: September 14, 2023 - Published By:
Source Cluster:
Republished By Plato

The healthcare industry has witnessed a remarkable transformation driven by technological advancements in recent years. One groundbreaking convergence is the fusion of Medical Technology (MedTech) and blockchain technology. This synergy has the potential to revolutionize healthcare by enhancing data security, interoperability, and patient-centric care. Enhanced Data Security: One of the foremost challenges in healthcare is ensuring the security and privacy of patient data. Medical records contain sensitive information that must be protected from unauthorized access and cyber threats. Blockchain technology offers a robust solution to this problem. Blockchain operates on

Gain Therapeutics Achieves Remarkable Breakthrough in Parkinson’s Disease Research

Source Node:
Time Stamp: August 29, 2023 8:16 AM - Modified On: August 29, 2023 - Published By:
Source Cluster:
Republished By Plato

Gain Therapeutics, Inc. (Nasdaq: GANX), a pioneering biotechnology company specializing in innovative allosteric small molecule therapies, has made significant strides in the fight against Parkinson's disease (PD). The Company's lead drug candidate, GT-02287, has demonstrated extraordinary potential in mitigating the effects of Parkinson's disease across two distinct preclinical models of the ailment. These findings suggest that GT-02287 has the capacity to alleviate Parkinson's disease pathology and enhance motor function. A notable highlight is the substantial reduction of plasma Neurofilament Light Chain (NfL) levels, an emerging biomarker for neurodegeneration. This advancement

Erez Capital Announces Additional Venture Partners

Source Node:
Time Stamp: August 4, 2023 6:52 AM - Modified On: August 4, 2023 - Published By:
Source Cluster:
Republished By Plato

Erez Capital, a emerging venture capital fund investing in disruptive technologies, is thrilled to announce the addition of new Venture Partners. Boston, Massachusetts, United States - August 3rd, 2023 — Erez Capital, a emerging venture capital fund investing in disruptive technologies, is thrilled to announce its addition of 40 Venture Partners to join the fund. These new partners will play an important role in the quickly developing artificial intelligence ecosystem - specifically in the proptech, medtech and fintech sectors. “This fund and its investments will represent the consensus of experts,

Verseon Acquires Edammo to Deepen Drug Discovery Approach

Source Node:
Time Stamp: November 13, 2022 3:46 AM - Modified On: November 17, 2022 - Published By:
Source Cluster:
Republished By Plato

Published: Nov 12th, 2022 | By Mark Terry Verseon Corporation has acquired Edammo, an artificial intelligence-focused company, to deepen its own AI-based drug discovery platform, the companies revealed Tuesday. Adityo Prakash, co-founder and CEO of Verseon and Ed Ratner, CEO at Edammo, discussed the acquisition with BioSpace. “We develop completely new drugs on the computer, atom by atom, then we make them in the laboratory,” Prakash said. "We’re changing how small molecule drugs are designed and developed with a level of efficiency that hasn’t been possible before.” He added that

Cuba Recognizes Cryptocurrencies | This Week in Crypto – Aug 30, 2021

Source Node: https://99bitcoins.com/bitcoin-news-summary-aug-30-2021/
Time Stamp: August 30, 2021 1:00 AM - Modified On: August 30, 2021 - Published By:
Source Cluster:
Republished By Plato

 MicroStrategy buys more bitcoin, Cuba recognizes cryptocurrencies and free BTC for everybody in town…but which town? These stories and more this week in crypto. NASDAQ-listed business intelligence company MicroStrategy announced yet another substantial purchase of Bitcoin, this time worth nearly $200 million. The firm added 3,907 bitcoin to its stash, at an average price of just over $45000 per coin bringing its total holdings to nearly 109,000 bitcoins. Cuba will recognize and regulate cryptocurrencies citing “reasons of socio-economic interest.” The central bank will set new rules for how to

New Lab Studies Suggest InBios COVID-19 POC Antigen Detection Test Will Detect Delta Variant

Source Node: https://www.prweb.com/releases/new_lab_studies_suggest_inbios_covid_19_poc_antigen_detection_test_will_detect_delta_variant/prweb18146251.htm
Time Stamp: August 22, 2021 9:00 AM - Modified On: August 22, 2021 - Published By:
Source Cluster:
Republished By Plato

SCoV-2 Ag Detect Rapid Test SEATTLE (PRWEB) August 22, 2021 InBios International Inc., a leading developer of diagnostic tests for emerging infectious diseases, announced today that laboratory studies suggest its SCoV-2 Ag Detect Rapid Test will detect the Delta variant (lineage B.1.617.2), which is responsible for a rapid rise of infections and deaths in the US and around the world. Initial studies suggest that InBios’ point-of-care antigen test will detect the Delta variant at rates similar to the USA-WA1-2020 isolate that was used to develop the assay. “Having a rapid